Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Post by peak2peakon Oct 11, 2017 7:28pm

118 Views

Post# 26801955

My old GEKKO friend...

TRVN seems to be down to the crunch as of today's NR. They are now focusing on getting their OLINVO crown jewel out to market with a year or less of fuel in the tank before they either have to close their doors or (more likely) get thrown a lifeline by diluting the stock with another equity issue. On the other hand, if they can successully get this out to market in 2018 she could be a rocketship ride especially if taken out by one of the BIG FISH in the pharmaceutical ocean.

Could be worth a punt as they say in the UK, although a high risk one-trick pony with nothing left in the pipeline if OLINVO is a commercial disappointment.

In other news, have you FERRETED out any good O&G plays now that Brent appears to be turning the corner?

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide